Granules India

    GRANULES
    Pharma
    ₹797.50
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹21,754 Cr

    P/E
    27.91
    Day range
    ₹790.30 – ₹818.00
    52-week range
    ₹529.85 – ₹923.65
    Volume
    11.98 L
    Open
    ₹815.50
    Prev close
    ₹815.50

    Latest results · Q2 FY27(consolidated)Revenue ₹1,560 Cr+20.3%Profit ₹182 Cr+39.2%Margin 11.7%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 66 / 100

    Factor percentiles

    Value55
    Quality61
    Momentum67
    Low volatility83

    Derived metrics

    Earn. yield
    3.6%
    Graham no.
    ₹369.93
    vs Graham
    -53.6%
    ROE ÷ P/B
    4.0%
    12-1 mom.
    +50.0%
    Return / vol
    1.53
    Magic Formula
    #279
    Piotroski
    5/6
    FCF yield
    1.1%
    PEG
    0.71

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Granules IndiaGRANULES₹21,754 Cr27.913.3713.5%16.0%22.0%0.17+20.3%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 7h ago

    Headlines about Granules India from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    31.0
    Price / Book
    3.31
    ROE (FY26)
    13.5%
    ROCE (latest year)
    16%
    Dividend yield
    0.22%

    Moving averages (NSE)

    20-day
    ₹812.96
    Price below
    50-day
    ₹834.49
    Price below
    200-day
    ₹752.33
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +5.9%
    Profit 3Y CAGR
    +4.8%
    Revenue YoY (Sep 2026)
    +20.3%
    Profit YoY (Sep 2026)
    +38.9%
    Operating margin
    22.0%
    Net margin
    11.7%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr8K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY21FY22FY23FY24FY25FY26FY27₹0₹0.5₹1₹1.5₹2

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales1,1561,1761,1809671,1381,1971,2101,2971,3881,4711,4771,560
    YoY Sales growth—-2—-19-2———————
    Expenses9059209217639079459631,0191,0801,1191,1381,222
    Operating Profit250256259203230252247278308352339338
    OPM %22%22%22%21%20%21%20%21%22%24%23%22%
    Other Income1223633-10-1-425211
    Interest292927262724242929332121
    Depreciation525353535764697274828084
    Profit before tax170176181128153198145176202262240243
    Tax %26%26%26%24%23%23%22%26%26%23%25%25%
    Net Profit12613013597118152113131150202180182
    EPS in Rs₹5.18₹5.35₹5.56₹4.01₹4.85₹6.27₹4.64₹5.38₹6.19₹8.13₹7.26₹6.67

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days62

    -24 days since Mar 2021

    Inventory Days326

    +121 days since Mar 2021

    Days Payable131

    -11 days since Mar 2021

    Cash Conversion Cycle256

    +106 days since Mar 2021

    Working Capital Days49

    -13 days since Mar 2021

    Strengths, risks & growth

    Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages. [1]

    Strengths

    • Company has reduced debt.

    Risks

    • Promoter holding has decreased over last quarter: -0.62%
    • The company has delivered a poor sales growth of 10.6% over past five years.
    • Company has a low return on equity of 13.7% over last 3 years.
    • Dividend payout has been low at 7.84% of profits over last 3 years

    Compounded Sales Growth

    10 Years
    +15%
    5 Years
    +11%
    3 Years
    +6%
    TTM
    +22%

    Compounded Profit Growth

    10 Years
    +17%
    5 Years
    +2%
    3 Years
    +5%
    TTM
    +37%

    Stock Price CAGR

    10 Years
    +23%
    5 Years
    +21%
    3 Years
    +30%
    1 Year
    +44%

    Return on Equity

    10 Years
    +17%
    5 Years
    +15%
    3 Years
    +14%
    Last Year
    +14%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter38.81%38.02%38.01%37.39%-0.62 pp
    FII13.55%15.31%17.50%20.25%+2.75 pp
    DII17.47%17.01%16.11%15.33%-0.78 pp
    Public30.15%29.67%28.36%27.04%-1.32 pp

    Filed with NSE for Sept 2026: promoters 37.39%, public 62.61%

    Analysts & fund holdings

    100%
    100% recommend buy
    8 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E27.9 vs 45.2
    Sector P/B6.05
    Beta0.69

    Who holds the shares, quarter by quarter

    Mutual funds 4.26% (+0.81 pp)
    Sept 25
    Dec 25
    Feb 26
    Mar 26
    Jun 26
    Sept 26
    • Promoters37.4%
    • Foreign institutions20.3%
    • Mutual funds4.3%
    • Insurance6.9%
    • Other domestic institutions4.1%
    • Retail12.7%
    • Others14.3%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Old Bridge Focused Fund0.64%3.06%-0.34 pp
    Aditya Birla SL Multi-Cap Fund0.62%1.91%+0.72 pp
    Aditya Birla SL Small Cap Fund0.56%2.09%+0.53 pp
    Sundaram Aggressive Hybrid Fund0.48%1.20%+0.41 pp
    Aditya Birla SL Value Fund0.41%1.34%-0.38 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    29.4%
    Downside volatility
    27.2%
    Worst 5% of days
    3.0%
    Average of that tail
    3.5%
    Max drawdown (1Y)
    13.2%
    Below its peak
    12.3%

    Against the market

    Beta vs Nifty 50
    0.78
    Correlation
    0.36
    Relative strength (3M)
    -11.3%
    ATR (14)
    4.0%

    Return

    Return 1M
    -3.4%
    Return 3M
    -7.4%
    Return 6M
    +9.0%
    Return 1Y
    +45.0%
    vs 200-day average
    +6.0%

    Momentum

    RSI (14)
    44.7
    MACD histogram
    0.52
    Stochastic %K
    36.7
    ADX (14)
    14.7
    +DI / −DI
    16.3 / 21.6
    Money flow index
    43.0

    Participation

    Delivery (20d avg)
    46.5%
    vs its 60-day baseline
    -2.9 pts
    Volume vs 20-day
    -0.3σ
    Close vs day's VWAP
    -0.4%
    52-week position
    72 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    5 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — failed
    Free cash flow
    ₹235 Cr
    FCF yield
    1.1%
    Cash conversion
    1.33
    Accruals ratio
    -0.026
    Net debt
    ₹156 Cr
    Net debt / equity
    0.02
    EV / sales
    3.72
    PEG
    0.71
    Capex intensity
    10.4%
    Revenue CAGR
    19.3%
    Profit CAGR
    12.7%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net buying ₹1462 Cr
    8 buys · ₹1462 Cr
    0 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Chigurupati Uma Devi
    Promoter Group · Preferential Offer
    Buy2,48,80,342₹364 Cr23 Oct 2026
    Priyanka Chigurupati
    Promoter Group · Preferential Offer
    Buy34,188₹50.0 L23 Oct 2026
    Pragnya Chigurupati
    Promoter Group · Preferential Offer
    Buy34,188₹50.0 L23 Oct 2026
    Harsha Chigurupati
    Promoter Group · Preferential Offer
    Buy34,188₹50.0 L23 Oct 2026
    Chigurupati Uma Devi
    Promoter Group · Preferential Offer
    Buy2,48,80,342₹1092 Cr23 Oct 2026
    Priyanka Chigurupati
    Promoter Group · Preferential Offer
    Buy34,188₹1.5 Cr23 Oct 2026
    Pragnya Chigurupati
    Promoter Group · Preferential Offer
    Buy34,188₹1.5 Cr23 Oct 2026
    Harsha Chigurupati
    Promoter Group · Preferential Offer
    Buy34,188₹1.5 Cr23 Oct 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹1.75

      Dividend - Rs 1.75 Per Share

      30 Jul 2026
      ex-date
    • dividend
      ₹1.50

      Dividend - Rs 1.50 Per Share

      31 Jul 2025
      ex-date
    • dividend
      ₹1.50

      Annual General Meeting/Dividend - Rs 1.50 Per Share

      30 Jul 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      3 Aug 2023
      ex-date
    • dividend
      ₹1.50

      Dividend - Rs 1.50 Per Share

      3 Aug 2023
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      22 Aug 2022
      ex-date
    • dividend
      ₹0.75

      Annual General Meeting/Dividend - Rs 0.75 Per Share

      19 Jul 2022
      ex-date
    • dividend
      ₹0.25

      Interim Dividend - Rs 0.25 Per Share

      17 Feb 2022
      ex-date
    • dividend
      ₹0.25

      Interim Dividend - Rs 0.25 Per Share

      24 Nov 2021
      ex-date
    • dividend
      ₹0.25

      Interim Dividend - Rs 0.25 Per Share

      5 Aug 2021
      ex-date
    • dividend
      ₹0.75

      Annual General Meeting/Dividend - Rs 0.75 Per Share

      28 Jul 2021
      ex-date
    • dividend
      ₹0.25

      Interim Dividend - Rs 0.25 Per Share

      8 Feb 2021
      ex-date
    • dividend
      ₹0.25

      Interim Dividend - Rs 0.25 Per Share

      28 Oct 2020
      ex-date
    • dividend
      ₹0.25

      Annual General Meeting/Dividend - Rs 0.25 Per Share

      5 Aug 2020
      ex-date
    • dividend
      ₹0.25

      Interim Dividend - Rs 0.25 Per Share

      28 Jul 2020
      ex-date
    • buyback
      Not available — not reported in this filing

      Buyback

      19 Mar 2020
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 0.25 Per Share

      30 Jan 2020
      ex-date
    • dividend
      ₹0.25

      Interim Dividend - Rs 0.25 Per Share

      31 Oct 2019
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/ Dividend - Re 0.25 Per Share

      21 Aug 2019
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 0.25 Per Share

      8 Aug 2019
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Schedule of Investor Meet

    Company Update
    Change In Corporate Office Address Of Registrar And Share Transfer Agent

    Change in Corporate Office Address of Registrar and Share Transfer Agent (RTA)

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of the Earnings Conference Call for Q2 and the half year of FY27

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio recording of the Earnings Conference call for Q2 and the half -year of FY27

    Company Update
    Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    Monitoring Agency Report for the quarter ended on September 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation to Analysts/Investors

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release

    Result
    Unaudited Financial Results (Standalone & Consolidated) For The Second Quarter And Half Year Ended On September 30, 2026

    Unaudited financial results for the second quarter and half year ended on September 30,2026

    Board Meeting
    Board Meeting Outcome for Outcome Of The Board Meeting Dated November 02, 2026.

    Outcome of the Board meeting dated November 02, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of the Earnings Conference call for Q2 and Half year of FY27.

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mrs Chigurupati Uma Devi, Mrs Priyanka Chigurupati, ....

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mrs Chigurupati Uma Devi, Mrs Priyanka Chigurupati, ....

    Insider Trading / SAST
    Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr. Krishna Prasad Chigurupati & PACs

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results For The Second Quarter And Half-Year Ended On September 30, 2026

    Granules India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve the unaudited financial results ....

    Filed with BSE (scrip 532482); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    • Buyback

      Granules India Limited

      12 Aug 2022
      Read on SEBI
    • Buyback - Post Offer Advertisement

      Granules India Limited - Post Offer Advertisement

      29 Jun 2020
      Read on SEBI
    • Buyback - Dispatch advertisement

      GRANULES INDIA LIMITED - Dispatch advertisement

      2 Jun 2020
      Read on SEBI
    • Buyback - Letter of Offer

      GRANULES INDIA LIMITED - Letter of Offer

      2 Jun 2020
      Read on SEBI
    • Buyback - Draft Letter of Offer

      GRANULES INDIA LIMITED - Draft Letter of Offer

      16 Mar 2020
      Read on SEBI

    Regulatory orders

    • Order

      Order in respect of SPS Share Brokers Pvt Ltd in the matter of Granules India Ltd

      12 Apr 2012
      Read on SEBI
    • Order

      Order in repect of Arun Kumar Dalmia, M/s Satya Securities Ltd and Basant Marketing Ltd in the matter of Granules India Ltd

      27 Aug 2010
      Read on SEBI
    • Adjudication order

      Adjudication order against Satya Securities Ltd. and Basant Marketing pvt. Ltd. in the matter of Granules India Ltd

      23 Jun 2009
      Read on SEBI
    • Order

      Order in the matter of C Krishna Prasad in the scrip of Granules India Ltd.

      14 Jan 2009
      Read on SEBI
    • Order

      Order in the matter of Pacific Corporate Services Limited in the scrip of Granules India Limited

      14 Jan 2009
      Read on SEBI

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 2 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Granules India: common questions

    Answered from the figures on this page.

    Granules India last traded at ₹797.50 (NSE, as of 18 Nov 2026). The last session moved it down 2.21%.

    Granules India is valued at about ₹21,754 crore (NSE, as of 18 Nov 2026).

    Granules India trades at a price-to-earnings ratio of 27.91 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Granules India has traded between ₹529.85 and ₹923.65 over the past 52 weeks, to 18 Nov 2026. It is currently 68% of the way up that range.

    Granules India (GRANULES) is classified under Pharma on this site's screener.